In June 2014, the U.S. Food and Drug Administration (FDA) approved two generic versions of celecoxib (Celebrex).
Developed by Pfizer, celexocib is used to treat rheumatoid arthritis, osteoarthritis, as well as other conditions.
Approval was granted to Mylan Pharmaceuticals, Inc. to market 50 mg celecoxib capsules, while Teva Pharmaceutical Industries received approval to market the drug in the following doses: 50 mg, 100 mg, 200 mg, and 400 mg, according to a bulletin from the FDA. Teva was…